Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.

Council of the Americas, with the support of Pfizer, convenes high-level roundtable discussions across Latin America.

Pfizer (PFE) closed at $25.32 in the latest trading session, marking a +1.12% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.48% for the day. Elsewhere, the Dow ...

Starboard Value is knocking on Pfizer’sPFE-2.92%decrease; red down pointing triangle door, demanding the drugmaker make changes to improve performance. The problem for the company and its new ...

Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as the president-elect has put forward vaccine skeptic Robert F. Kennedy ...

So last year the company created a phone line for doctors and patients to call Pfizer directly for help. Pfizer now credits that and other changes for a 31% increase in Nurtec’s U.S. sales last ...

Pfizer (PFE) made some major changes to its diversity, equity, and inclusion (DEI) webpage on Thursday, joining other major American corporations that have recently aligned themselves closer with ...

Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted. Pharmaceutical titan Pfizer (NYSE: PFE) is a case in point.